Cystometry Using a Novel Microsensor System in Patients With Neurogenic Bladder Dysfunction (PEPRE2)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Nesoddtangen
-
Oslo, Nesoddtangen, Norway, N-1450
- Sunnaas Rehabilitation Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Documented traumatic or non-traumatic spinal cord injury
- Documented neurogenic bladder dysfunction by previous cystometry
- More than 3 months after injury
- Subject is able to communicate in Norwegian
- Subject is able and willing to sign informed consent
- Subject is able to complete all study requirements
Exclusion Criteria:
- History or evidence of previous urological or lower abdominal abnormalities from disease or surgery
- Use of anti-platelet or anti-coagulant other than low molecular weight heparin or acetylsalicylic acid which cannot be discontinued
- Symptomatic urinary tract infection
- Hemophilia or other clotting disorders that cause bleeding diathesis
- Any condition or situation, which, in the investigator's opinion, puts the subject at significant risk, could confound the study results, or may interfere significantly with the subject's participation in the study
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Simulataneous bladder pressure recording
In all patients recruited, the pressure will be recorded simultaneously with the conventional and novel pressure recording systems in the bladder.
The procedure will be done according to the International Continence Society's (ICS) recommended indications for the procedure.
|
The procedure will be done according to the International Continence Society's (ICS) recommended indications for the procedure.
The investigational device is inserted into a 12F single-use hydrophilic catheter.
After correct positioning is verified by ultrasound and x-ray, the investigational device is released from the insertion catheter.
The insertion catheter is then carefully removed, securing the correct positioning of the investigational device inside the bladder.
The investigational device is connected to a data logger.
In the conventional device, the intravesical pressure is recorded using a water perfused 3F catheter with a 3 ml/hour perfusion rate.
The 3F catheter is hooked on an 8F catheter to facilitate introduction into the bladder.
The catheters used for pressure transmission are connected to external transducers and a computer with software processing the recording
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bladder pressure
Time Frame: 24 hours
|
The bladder pressure recorded simultaneously by a conventional clinical system and the prototype will be used for a systemstic comparison analysis in the time-amplitude and the time-frequency domains.
|
24 hours
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Advert effects monitoring and resolution
Time Frame: 72 hours
|
Subjects will be examined for any subjective or objective adverse events.
The transurethral technique is well-known, and the complication rates are very low.
However, there are known complications such as urinary tract infection, hematuria, pain, retention, and autonomic dysreflexia in tetraplegics.
Subjects will be routinely examined for all these conditions, and if any of them occur, adequate treatment will be initiated according to hospital guidelines.
The small-sized sensor tube (Ø ≈ 1.2 mm) provides a minimally invasive clinical procedure.
In case of perforation, the lesion will be small.
|
72 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Urologic Diseases
- Urinary Bladder Diseases
- Neurologic Manifestations
- Wounds and Injuries
- Trauma, Nervous System
- Spinal Cord Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Spinal Cord Injuries
- Urinary Bladder, Neurogenic
Other Study ID Numbers
Other Study ID Numbers
- SUPRE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.